Medscape

Home CME Conference Coverage Resource Centers Library Discussions
November 5, 2003

Email to a Colleague Printable Version

Publication Logo

Suicidality May Occur in Children on Antidepressants for MDD


Medscape Staff Report

Oct. 27, 2003 Suicidality (both suicidal ideation and suicide attempts) in clinical trials of various antidepressant drugs in pediatric patients with major depressive disorder (MDD) has been reported, the U.S. Food and Drug Administration (FDA) said today.

Although "occurrences of suicidality are not unexpected in patients with MDD, preliminary data suggest an excess of such reports for patients assigned to several of these antidepressant drugs compared with those assigned to placebo," the FDA stated in a public health advisory posted on its Web site.

FDA has completed a preliminary review of the reports for eight antidepressant drugs (citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, and venlafaxine), which were studied under the pediatric exclusivity provision. Additional data and analysis, as well as a public discussion of available data, are needed, according to an e-mail sent today from MedWatch, the FDA's safety information and adverse event reporting program.

An advisory committee meeting will be held before the Psychopharmacologic Drugs Advisory Committee and the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee on Feb. 2, 2004.

Reviewed by Gary D. Vogin, MD



Related Links

Resource Centers

Depression

External Links

FDA Public Health Advisory






Medscape 2003. 2003 WebMD Inc.

Related Resources
Clinical articles on this topic

SEARCH
 
Medscape    
DrugInfo
MEDLINE
  About Medscape    Privacy & Ethics    Terms of Use    Help    WebMD Health

All material on this website is protected by copyright, Copyright 1994-2003 by Medscape. This website also contains material copyrighted by 3rd parties. Medscape requires Netscape or Microsoft browsers in versions 5 or higher.